ReviewInternational journal of nanomedicine2026
Delivery of TCM Monomers Using Blood Cell Membrane Coated Biomimetic Nanoparticles to Target CVD.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell membrane-coated nanoparticles are receiving increasing recognition for their potential in treating cardiovascular diseases (CVD). This novel drug delivery system, featuring drug-loaded nanoparticles modified by naturally derived cell membranes, is capable of precisely targeting diseased sites, improving drug bioavailability, evading immune surveillance, and prolonging half-life. These targeted and protective behaviors are driven by the preservation of functional surface proteins on the cell membrane, such as CD47 for inhibiting macrophage phagocytosis and specific integrins for targeting disease sites. More importantly, by translating inherent multi-target bioactivities into localized therapeutic outcomes, this biomimetic nanotechnology can significantly improve the drug delivery of TCM monomers, whose therapeutic effects on the treatment of CVD have been widely recognized. However, their clinical translations have historically been restricted by low bioavailability and unfavorable pharmacokinetics. Therefore, this review underscores recent developments in cell membrane-coated nanocarriers for treating CVD. It then highlights the application of traditional Chinese medicine (TCM) monomers delivered via cell membrane-coated nanoparticles in atherosclerosis, thrombosis, myocardial infarction, and ischemic stroke. Finally, this work discusses the challenges for clinical translation of these biomimetic nanocarriers by highlighting the technical complexities of source cell collection, membrane extraction efficiency, and large-scale manufacturing standardization that currently block clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.